Compare ResMed Inc. (RMD) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Growth Index Fund ETF — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Vanguard Growth Index Fund ETF trades at $92 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 12.1× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Vanguard Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| RMD | VUG | |
|---|---|---|
Market Cap | $31.89B | $384.60B |
Volume | 618,314 | 5,662,307 |
Sector | Health | Sector/Thematic |
52-Week High | $277.88 | $92.64 |
52-Week Low | $182.82 | $70.00 |
Typical Hold Time | 51 Days | 47 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
VUG trades at $92.42, down 0.24% on the day, with a bullish technical outlook supported by moving averages but showing overbought conditions on shorter-term RSI readings. The ETF maintains strong long-term performance credentials with 11-12% average annual returns since 2004, though current concentration in mega-cap tech stocks presents both opportunity and risk. Recent dividend activity shows minimal income generation with a $0.09 distribution scheduled for September 2026.
The growth-focused ETF offers exposure to market-leading companies but faces concentration risk with over 36% in three holdings. Long-term investors benefit from Vanguard's low-cost structure and historical outperformance, though near-term technical indicators suggest potential consolidation. Market sentiment remains positive for buy-and-hold strategies despite recent value stock outperformance in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
